These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30819914)

  • 21. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acalabrutinib for adults with mantle cell lymphoma.
    Jurczak W; Długosz-Danecka M; Wang M
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.
    Bye AP; Unsworth AJ; Desborough MJ; Hildyard CAT; Appleby N; Bruce D; Kriek N; Nock SH; Sage T; Hughes CE; Gibbins JM
    Blood Adv; 2017 Dec; 1(26):2610-2623. PubMed ID: 29296914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Jain P; Kanagal-Shamanna R; San Lucas FA; Nastoupil L; Romaguera J; Fayad L; Oki Y; Westin JR; Medeiros LJ; Wang M; Fowler N
    Br J Haematol; 2018 Sep; 182(5):718-723. PubMed ID: 28771675
    [No Abstract]   [Full Text] [Related]  

  • 26. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
    Dobie G; Kuriri FA; Omar MMA; Alanazi F; Gazwani AM; Tang CPS; Sze DM; Handunnetti SM; Tam C; Jackson DE
    Blood Adv; 2019 Dec; 3(24):4298-4311. PubMed ID: 31869418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
    Bond DA; Maddocks KJ
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
    Bye AP; Unsworth AJ; Vaiyapuri S; Stainer AR; Fry MJ; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2326-35. PubMed ID: 26359510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting BTK in CLL: Beyond Ibrutinib.
    Bond DA; Woyach JA
    Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
    Estupiñán HY; Wang Q; Berglöf A; Schaafsma GCP; Shi Y; Zhou L; Mohammad DK; Yu L; Vihinen M; Zain R; Smith CIE
    Leukemia; 2021 May; 35(5):1317-1329. PubMed ID: 33526860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib: a paradigm shift in management of CLL.
    Badar T; Burger JA; Wierda WG; O'Brien S
    Expert Rev Hematol; 2014 Dec; 7(6):705-17. PubMed ID: 25387837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
    Aguilar C
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):481-487. PubMed ID: 29995658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
    Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
    Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Wolska-Washer A; Robak T
    Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
    Wu J; Zhang M; Liu D
    J Hematol Oncol; 2016 Mar; 9():21. PubMed ID: 26957112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.